Drug survival of metformin in patients with hidradenitis suppurativa

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSENENT-VALERO, Marina
dc.contributor.authorMATIJASEVICH, Alicia
dc.contributor.authorJARA-RICO, Noelia
dc.contributor.authorSIVERA, Francisca
dc.contributor.authorPASCUAL, Jose C.
dc.date.accessioned2024-04-05T19:34:22Z
dc.date.available2024-04-05T19:34:22Z
dc.date.issued2023
dc.description.abstractDespite there being published studies on the survival of oral retinoids and biological drugs in people with hidradenitis suppurativa (HS), there is little scientific evidence on the use of metformin in this setting. We conducted a single-centre, retrospective cohort study in Spain, between January 2015 and December 2021 to determine the drug survival of metformin at 12 months in people with HS in a real-world setting. We concluded that drug survival of metformin is relatively long: half the patients were still on the drug after 1 year of treatment and one in five patients were still on the drug after 2 years.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexScopus
dc.description.indexDimensions
dc.description.indexWoS
dc.identifier.citationBRITISH JOURNAL OF DERMATOLOGY, v.190, n.1, p.125-127, 2023
dc.identifier.doi10.1093/bjd/ljad364
dc.identifier.eissn1365-2133
dc.identifier.issn0007-0963
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/58967
dc.language.isoeng
dc.publisherOXFORD UNIV PRESSeng
dc.relation.ispartofBritish Journal of Dermatology
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright OXFORD UNIV PRESSeng
dc.subject.wosDermatologyeng
dc.titleDrug survival of metformin in patients with hidradenitis suppurativaeng
dc.typearticleeng
dc.type.categorylettereng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryEspanha
hcfmusp.affiliation.countryisoes
hcfmusp.author.externalSENENT-VALERO, Marina:Dr Balmis Gen Univ Hosp, Alicante Inst Hlth & Biomed Res ISABIAL, Dermatol Dept, Alicante, Spain
hcfmusp.author.externalJARA-RICO, Noelia:Dr Balmis Gen Univ Hosp, Alicante Inst Hlth & Biomed Res ISABIAL, Dermatol Dept, Alicante, Spain
hcfmusp.author.externalSIVERA, Francisca:Miguel Hernandez Univ, Dept Med, Elche, Spain; Elda Univ Hosp, Rheumatol Dept, Alicante, Spain
hcfmusp.author.externalPASCUAL, Jose C.:Dr Balmis Gen Univ Hosp, Alicante Inst Hlth & Biomed Res ISABIAL, Dermatol Dept, Alicante, Spain
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcALICIA MATIJASEVICH MANITTO
hcfmusp.description.beginpage125
hcfmusp.description.endpage127
hcfmusp.description.issue1
hcfmusp.description.volume190
hcfmusp.origemWOS
hcfmusp.origem.dimensionspub.1164361507
hcfmusp.origem.pubmed37751385
hcfmusp.origem.scopus2-s2.0-85181237492
hcfmusp.origem.wosWOS:001096585800001
hcfmusp.publisher.cityOXFORDeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceBadr D, 2013, J EUR ACAD DERMATOL, V27, P1329, DOI 10.1111/jdv.12116eng
hcfmusp.relation.referenceBouwman K, 2022, AM J CLIN DERMATOL, V23, P905, DOI 10.1007/s40257-022-00725-9eng
hcfmusp.relation.referenceIngram JR, 2019, BRIT J DERMATOL, V180, P1009, DOI 10.1111/bjd.17537eng
hcfmusp.relation.referenceJennings L, 2020, J DERMATOL TREAT, V31, P261, DOI 10.1080/09546634.2019.1592100eng
hcfmusp.relation.referencePrens LM, 2021, BRIT J DERMATOL, V185, P177, DOI 10.1111/bjd.19863eng
hcfmusp.relation.referenceRing HC, 2022, JAMA DERMATOL, V158, P184, DOI 10.1001/jamadermatol.2021.4805eng
hcfmusp.relation.referenceVerdolini R, 2013, J EUR ACAD DERMATOL, V27, P1101, DOI 10.1111/j.1468-3083.2012.04668.xeng
hcfmusp.relation.referenceVilanova I, 2018, J EUR ACAD DERMATOL, V32, P820, DOI 10.1111/jdv.14894eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication80ba0f0e-5cf3-4950-adeb-120ca4be5a71
relation.isAuthorOfPublication.latestForDiscovery80ba0f0e-5cf3-4950-adeb-120ca4be5a71
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPR